Peter Verhamme

Research interests

Publications

• Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00456-1

• American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism

  Blood Advances · 2020 · https://doi.org/10.1182/bloodadvances.2020001830

• Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1814051

• Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant

  JAMA Internal Medicine · 2019 · https://doi.org/10.1001/jamainternmed.2019.2431

• Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes

  JAMA · 2019 · https://doi.org/10.1001/jama.2019.9811

• Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

  Gastroenterology · 2019 · https://doi.org/10.1053/j.gastro.2019.05.056

• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

  EP Europace · 2018 · https://doi.org/10.1093/europace/euy054

• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

  European Heart Journal · 2018 · https://doi.org/10.1093/eurheartj/ehy136

• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

  The Lancet · 2017 · 10.1016/s0140-6736(17)32409-1

• Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1700518

• Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1709118

• Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1711948

• Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

  The Lancet · 2017 · 10.1016/s0140-6736(17)32458-3

• Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial

  Canadian Journal of Cardiology · 2017 · https://doi.org/10.1016/j.cjca.2017.06.001

• Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1707278

• Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

  EP Europace · 2015 · https://doi.org/10.1093/europace/euv309

• Idarucizumab for Dabigatran Reversal

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1502000

Current projects

No projects listed.